In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
The search results provided do not contain any specific information about an oncology expert meeting under FDA Commissioner Makary, nor do they mention cancer drugs from J&J, Pfizer, Roche, and UroGen being spotlighted at such a meeting. The search results focus primarily on Dr. Marty Makary's appointment as FDA Commissioner, his vision for the agency, and some policy changes he has announced, but do not provide details about any oncology-specific meetings or discussions about specific cancer drugs from these companies.
The available information covers Makary's confirmation as FDA Commissioner in March 2025, some of his early priorities and policy changes (such as limiting industry representation on FDA advisory committees), and his general approach to leading the agency. However, there is no mention of an oncology expert meeting or specific cancer drug evaluations from the companies mentioned in the query.
Without relevant information in the search results, I cannot provide details about the oncology expert meeting or the cancer drugs referenced in the query.